MetaCap

Amylyx Pharmaceuticals (AMLX) vs Xeris Biopharma (XERS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xeris Biopharma (XERS) has outperformed Amylyx Pharmaceuticals (AMLX) over the past year, gaining 148.5% versus a gain of 77.4%. Amylyx Pharmaceuticals is the larger company by market cap ($3.35 billion vs $3.10 billion), about 1.1 times the size, while Xeris Biopharma is growing revenue faster (+43.7% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMLX+77.37%XERS+148.46%
+180%+74%-32%
Nov 21, 20251 yearNov 20, 2026
AMLX+44.00%XERS+562.89%
+596%+236%-124%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMLX versus XERS key metrics
MetricAMLXXERS
Share price$26.02$16.97
Market cap$3.35B$3.10B
1-day change-0.69%+2.11%
YTD return+115.40%+116.18%
1-year return+77.37%+148.46%
5-year return—+682.03%
Forward P/E—63.64
EPS (TTM)$-1.43$-0.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$291.85M
Revenue growth (YoY)-100.00%+43.72%
Net income (latest FY)$-144.74M$554.00K
Gross margin—85.41%
Operating margin—8.53%
Net margin—0.19%
52-week high$41.14$17.28
52-week low$10.83$5.25
Distance from 52-week high-36.75%-1.79%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+65.26%+1.89%
Average volume1.53M2.86M
Shares outstanding128.56M182.70M
Employees136435
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XERS has outperformed AMLX by 71.1 percentage points over the past year.
  • Xeris Biopharma grew revenue faster in its latest fiscal year (+43.72% vs -100.00%).

About Amylyx Pharmaceuticals

AMLX stock →

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.

Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees

About Xeris Biopharma

XERS stock →

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees

AMLX vs XERS FAQ

Which is bigger, Amylyx Pharmaceuticals or Xeris Biopharma?

Amylyx Pharmaceuticals (AMLX) is larger, with a market capitalization of $3.35B compared with $3.10B for Xeris Biopharma (XERS).

Which stock has performed better over the past year, AMLX or XERS?

XERS returned +148.46% over the past 12 months, compared with +77.37% for AMLX (price return, excluding dividends). Past performance does not predict future results.

Are Amylyx Pharmaceuticals and Xeris Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons